Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients With Actinic Keratosis - a Double-blind Randomized Controlled Trial

Next Previous
Trial Profile

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients With Actinic Keratosis - a Double-blind Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 503 (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms VAXAK

Most Recent Events

  • 12 Jul 2024 Status changed from active, no longer recruiting to completed.
  • 01 Jul 2024 Planned End Date changed from 1 Jun 2035 to 19 Jun 2034.
  • 08 Nov 2023 Planned End Date changed from 1 Feb 2024 to 1 Jun 2035.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top